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Abstract
The 4th expert meeting of the MiSOT (Mesenchymal Stem Cells in Solid Organ Transplantation)
Consortium took place in Barcelona on the 19th and 20th of October 2012. This meeting focused
on the translation of pre-clinical data into early clinical settings. This position paper highlights the
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main topics explored on the safety and efficacy of mesenchymal stem cells (MSC) as a therapeutic
agent in solid organ transplantation and emphasizes the issues (proper timing, concomitant
immunossupression, source and immunogenicity of MSC and oncogenicity) that have been
addressed and will be followed up by the MiSOT Consortium in future studies.
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The MiSOT (Mesenchymal Stem Cells in Solid Organ Transplantation) Consortium was
founded to enable effective collaboration between research groups working in the
application of adherent stem cell products in solid organ transplantation (1–2).
The research teams involved in the innovative use of mesenchymal stem cells (MSC) in
solid organ transplantation aim to bring tangible benefits to the clinical transplant setting,
improving transplant outcomes and patient quality of life. The main goals of the MiSOT
meeting are to foster the continued cooperation between members of the community and to
discuss the challenges faced in advancing the application of MSC in clinical transplantation
and how these should be addressed.
Clinical application
MSC are one of the most promising cell populations for cell-based immunomodulatory
therapy in solid organ transplantation. During the last 2 years MSC have been applied to the
clinical setting in several phase I trials (3–5) and developments in ongoing or trials nearing
initiation (Detry et al-Liege (6), Remuzzi et al-Bergamo (7), Dahlke et al-Regensburg (8)
communications at 4th MiSOT meeting and registered trials) were presented at this meeting.
To date, MSC administration in clinical transplantation has proven relatively safe and
feasible (Table 1). There are indications of efficacy in preventing acute cellular rejection and
reducing induction and maintenance immunosuppressive regimens (4), inducing long-term
stable graft function (3) and reducing tubulitis and interstitial fibrosis/tubular atrophy in
some patients (5). In addition, MSC may induce systemic alloimmune modulation, since a
donor specific down regulation of the proliferation of peripheral blood mononuclear cells
was reported (5) and the ratio of regulatory T cells (Tregs) versus memory T cells was
increased (3).
The outcomes of these trials have highlighted several issues (proper timing, concomitant
immunosuppression, source and immunogenicity of MSC and oncogenicity) that need to be
promptly addressed. This needs to be supported by applied research regarding specific
primary end-points and reference controls. It is clear that new evidence from basic research
can provide valuable information for the design of future clinical trials.
The timing of therapeutic MSC administration remains a matter of intense debate.
Depending on the therapeutic goal and concurrent immunosuppressive drugs, different
timing of MSC administration will be necessary. To induce a more tolerogenic state and
prevent early acute rejections, MSC may be given around the moment of transplantation.
However, while early post-transplantation injection promoted long-term pro-tolerogenic
effects, it also induced transient renal dysfunction in two kidney transplant recipients (3).
Therefore pre-transplantation infusion of MSC is now investigated. For treatment of
ongoing (subclinical) chronic rejection, MSC may be given later after transplantation when
graft function is still stable or when graft function is deteriorating. In the only clinical study
so far administering MSC six months after transplantation, kidney function remained stable.
The long term effects of MSC on chronic rejection are still awaited.
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The choice of concomitant immunosuppression is another point of discussion. Preclinical
studies suggest that Mycophenolic acid/Mycophenolate mofetil (MPA/MMF) may have a
synergistic immunomodulatory effect with MSC (9) while calcineurin inhibitors (CNI) may
not do so (10). However, the safety trials published so far in kidney transplantation used
CNIs as concomitant immunosuppression. This suggests that distinct drug combinations in
association with MSC open an avenue of improvement for future clinical trials. Further, the
use of induction therapy is still at an exploratory stage. Tan et al. (4) suggest that MSC can
substitute the induction therapy with anti-IL-2 receptor (Basiliximab), whereas Perico et al.
(3) concomitantly used Basiliximab and T cell depletion (Thymoglobulin) as induction
therapy to facilitate the immunomodulatory properties of MSC.
The tissue source of MSC is an important area of consideration for future phase II/III trials.
Besides BM-MSC, emerging data also suggest the high therapeutic potential of MSC
isolated from adipose tissue (AT), cord blood (CB) and other human tissues. Some of these
tissues are easily accessible and may therefore represent a suitable source of MSC.
In addition to the tissue source, the immunogenicity of MSC may have both economic and
logistic implications and impact on the viability of MSC-based therapies. MSC are very
likely not completely immunoprivileged as they express HLA class I and can be induced to
express HLA class II. The use of autologous MSC has been the choice of treatment of
kidney transplantation trials so far; in this regard, in renal transplantation autologous MSC
from uremic patients might be used as MSC from end-stage renal disease patients have
proven as efficiently immunosuppressive as those from healthy individuals (11)(12).
However, some recently designed trials have focused on the use of allogeneic MSC
produced in either in-house GMP facilities or by commercial cell production companies.
The availability of an off-the-shelf product commercially produced may overcome some of
the logistic limitations associated with autologous MSC in the organ transplant setting and
allow institutions without GMP facilities or a capacity to isolate MSC to actively participate
in this field of research. Moreover, the allogeneic MSC product can be easily standardized
and therefore provides more comparable results among different trials. Standardized
expansion is a critical point since specific effects of expansion details can induce variation
in the product efficacy and is a concern of the group that is seeking for new ideas to
overcome this inter-trials disparity. Although the immunogenicity of allogeneic MSC needs
further study to prove safe in clinical trials, a very recent pilot study showed that donor-
derived bone marrow MSC safely allowed reduction of conventional dose of tacrolimus in
living-related kidney transplant recipients, at least during 12 months follow-up (13). So,
results obtained from ongoing trials are eagerly awaited in order to give a better judgment
regarding this problem and make a decision on how to proceed.
Encouragingly, the potential for MSC maldifferentiation, an area of concern for the
transplantation community and the MiSOT group in particular, may be less of an issue than
previously thought. Multiple studies have failed to find evidence for malignant
transformation of MSC (14). Indeed earlier reports on the MSC maldifferentiation have been
retracted following evidence that the MSC cultures reported were contaminated with tumor
cell lines (15–16). However, as research into MSC malignant transformation is ongoing,
investigators must remain cautious on the interpretation of such findings.
Another focus of safety concerns in current clinical applications with MSC is a potential
increased susceptibility to opportunistic infections. Reinders et al (5) reported the
development of opportunistic viral infections in 3 out of 6 patients, indicating that care
should be taken with the potency of the immunosuppressive effect of MSC. In contrast Tan
et al (4) showed a reduced susceptibility to infections in their MSC-treated patients
compared to the regular immunosuppressive regimen. The effects of MSC
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immunosuppression need to be carefully analyzed and if necessary exclusion criteria defined
before moving forward with MSC-based therapy in organ transplantation.
Regulatory aspects
The goal of reducing severe side effects of pharmaceutical immunosuppression justifies
attempts to implement novel cellular therapies. While many authorities remain apprehensive
of emerging cell-based immunomodulation therapies, one must be mindful that regulatory
agencies face a struggle to ensure that regulations and guidelines keep pace with the
development of new technologies. The differing regulatory requirements between the EU
and the USA exacerbate this situation further.
In Europe, centralised and national regulations contain provisions for several cell therapy
development strategies (17). Certain cell therapy applications may not follow the classical
medicinal product development process with standard clinical trials. The European
regulatory framework provides an option for cell therapy products under a Hospital
Exemption (HE) clause. In order to qualify for HE, cell therapy products have to be prepared
on a non-routine basis according to specific quality standards, and have to be used within the
same Member State in a hospital under the exclusive professional responsibility of a medical
practitioner. Since HE is not a centralised procedure and Member States have to introduce
national implementation tools, the requirements and conditions for the authorisation will
vary from country to country. Activities required to implement the HE clause should be
accomplished in the majority of the EU states by the end of 2012. Nevertheless, currently, it
is uncertain if HE is the most promising approach of cellular therapy development for either
the scientific, medical or commercial communities in Europe.
Centralised evaluation by the European Medicines Agency is required for cell therapy
product marketing authorisation in the EU. Whilst there have been no MSC-based medicine
authorisations in the EU, a number of MSC and other cell therapy products are marketed
under conditional marketing authorisations in other regions (17).
The challenges of transferring a cell-based therapy from bench to bedside under a regulatory
framework that crosses multiple responsible authorities, EU members and continents are
difficult to overcome but in the meeting we learned that such translation is feasible.
Experimental news
Pre-clinical studies have revealed that although MSC remain in circulation for a very short
period of time (18), a powerful therapeutic effect is observed. This opens the door to
speculate about mechanisms of MSC action and may provide an indication to the importance
of interactions between MSC and the innate immune system that might shape MSC
responsiveness (reviewed in (19)). Preliminary results obtained from mice injected with
syngeneic MSC show a transient induction of inflammatory mediators, while later being
protected from the mounting of inflammatory reaction in response to LPS (Hoogduijn et al,
Communication at the 4th MiSOT meeting).
This phenomenon leads to the gradual removal of MSC from the recipient and has
regulatory implications. The host-controlled, transient presence of MSC may reduce the
concerns regarding the persistence of implanted cells longer than required, while preserving
their therapeutic efficiency.
The study of the immunomodulatory properties of MSC and the insight already gained on
their mechanisms of action will contribute to develop more refined therapeutic approaches.
Besides the well-known effect on T cell proliferation, new and improved studies have
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unraveled the effect of MSC on the induction of Tregs, Th17 cells and regulatory
macrophages depending on the inflammatory milieu encountered as well as a direct effect on
B cells inhibiting their differentiation into immunoglobulin producing plasmablasts.
MSC possess a broad therapeutic spectrum in transplantation, being efficient not only in
alleviating the alloimmune reaction but also in reducing the cell infiltrates and inflammatory
mediators involved in ischemia/reperfusion injury.
In addition, beyond the attractive intrinsic features of MSC, their potential use as vectors or
biological factories (cytokines, chemokines, receptors, growth factors) through ex vivo
genetic engineering might allow additional therapeutic benefits to enhance organ
transplantation outcomes.
Conclusions
In 2012, the MiSOT Consortium shared the experiences gained from the first clinical trials
performed using MSC in solid organ transplantation and new pre-clinical and experimental
studies. The results are encouraging, but additional knowledge is required before MSC-
based therapies can be broadly applied to patients. Well designed trials with clearly defined
end-points, appropriate controls and extensive immune monitoring are the key to succeed
with the advancement of MSC therapy. The MiSOT expert meeting learned how MSC
therapy has already proven safe in clinical trials and effective in preclinical models and
highlighted the work required to translate this into a mainstream therapeutic approach.
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